Add BrightSurf on Google Email

Treatment with KCL-286, a first-in-class retinoic acid receptor-ß (RARß) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease


Coverage from 3 institutions